Coherus Sells Udenyca to Intas for Up to $558M to Focus on Cancer Immunotherapy

Coherus BioSciences is shifting its focus from biosimilars to cancer immunotherapies through the divestment of Udenyca, a biosimilar of Amgen's Neulasta, to Intas Pharmaceuticals for up to $558 million. This strategic sale allows Coherus to reallocate resources toward novel cancer treatments, particularly leveraging its brand-name drug Loqtorzi. The agreement includes an upfront payment of $483.4 million, with potential sales milestone payments of up to $75 million, and is expected to be finalized by the end of the first quarter of 2025[1][2]. Coherus plans to use the proceeds from this transaction to meet existing financial commitments, including repaying convertible notes and royalty obligations, while transferring some employees associated with Udenyca to Intas[2].